GLUE - Monte Rosa Therapeutics, Inc.
| Chiusura precedente | 7,36 |
| Aperto | 7,44 |
| Denaro | 7,13 x 800 |
| Lettera | 7,20 x 1400 |
| Min-Max giorno | 7,09 - 7,59 |
| Intervallo di 52 settimane | 4,40 - 12,62 |
| Volume | |
| Media Volume | 194.977 |
| Capitalizzazione | 356,55M |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,42 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 19,63 |
GlobeNewswireMonte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company is scheduled to present at the following investor and industry events in June: BIO International Healthcare Conference in Boston; panel entitled “From Serendipity to Rational Design, Redefining the Rules of Molecular Glue Discovery” on June 5 at 1PM ET in Session Room 208Jefferies
- GlobeNewswire
Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases
Preclinical data establish MRT-6160’s ability to potently and selectively degrade VAV1 and inhibit disease progression in autoimmunity models, supporting potential applications across multiple autoimmune diseasesPlanned IND filing in the first half of 2024 BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced its second development candidate, MRT
- GlobeNewswire
Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
On track to present initial data from Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors in the second half of 2023Cash runway into 2025 supports operations and advancement of pipeline of novel molecular glue degraders to key inflection points BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial resu
- GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023
Preclinical data demonstrate preferential activity of MRT-2359, an orally bioavailable GSPT1-directed molecular glue degrader, in MYC-driven tumor cellsPhase 1/2 clinical trial of MRT-2359 ongoing in MYC-driven solid tumors, including lung cancer; disclosure of initial data from Phase 1 arm of study expected in second half of 2023 BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrade
- GlobeNewswire
Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors
BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Jan Skvarka, Ph.D., MBA to its Board of Directors. Dr. Skvarka is an accomplished biopharmaceutical executive bringing over three decades of extensive operational, strategic and financial expertise to the Board. "We are delighted to have Dr. Skvarka join our Board of Direc
- GlobeNewswire
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Phase 1/2 clinical trial evaluating MRT-2359 for treatment of MYC-driven solid tumors ongoingDisclosure of initial data from Phase 1 arm of study expected in second half of 2023MRT-2359 received Fast Track designation from FDA for treatment of patients with previously treated, metastatic non-small cell lung cancer (NSCLC) with L-MYC or N-MYC expressionNomination of multiple development candidates anticipated in 2023Year-end 2022 cash balance of approximately $268 million, with cash runway into 2
- GlobeNewswire
Monte Rosa Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company is scheduled to participate in fireside chats and industry panels, as well as present at the following upcoming investor events: Guggenheim Oncology Conference in New York, on February 9, at 2:45 p.m. ETBMO Virtual Biopharma Spotlight Series on February 10, 2023, at 10:00 a.m. ETSVB Securities V
- GlobeNewswire
Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023
MRT-2359 received Fast Track designation from the FDA for the treatment of patients with previously treated, metastatic non-small cell lung cancer (NSCLC) with L-MYC or N-MYC expressionDisclosure of initial data from Phase 1 arm of ongoing Phase 1/2 clinical trial evaluating MRT-2359 expected in second half of 2023Nomination of multiple additional development candidates anticipated in 2023Company to present pipeline and corporate updates at 41st Annual J.P. Morgan Healthcare Conference on Wednes
- GlobeNewswire
Monte Rosa Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 11, 2023, at 11:15 a.m. PT. The webcast of the presentation will be accessible via the “Events & Presentations” section of the company’s investor site at https:
- GlobeNewswire
Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates
– Initiated Patient Dosing in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors – – Progressed VAV1 Molecular Glue Degrader Program into Lead Optimization – BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the third quarter, ended Septembe
- GlobeNewswire
Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company has dosed the first patient in its Phase 1/2 clinical trial evaluating MRT-2359 for the treatment of MYC-driven solid tumors, including lung cancer. MRT-2359 is a potent, selective and orally bioavailable GSPT1-directed MGD, designed to disrupt protein synthesis in MYC-driven tumors, and lead to
- GlobeNewswire
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader-based medicines, today announced the company will participate in the following upcoming investor conferences: Credit Suisse 31st Annual Healthcare Conference (Nov. 7-10) Jefferies 13th Annual London Healthcare Conference (Nov. 15-17) Piper Sandler 34th Annual Healthcare Conference (Nov. 29-Dec. 1) Where applicable, archived webcasts can be acces
- GlobeNewswire
Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium
– New and Updated Preclinical Data Highlight Potential of GSPT1-directed Molecular Glue Degrader (MGD) MRT-2359 in the Treatment of MYC-driven Cancers – – Novel and Proprietary AI/Machine Learning Engine Characterizes Protein Surfaces, Expands Insights into Neosubstrate Universe, Reprogrammable Ligases and MGDs – BOSTON, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ann
- GlobeNewswire
Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader
– Phase 1/2 Clinical Trial in Patients with MYC-driven Solid Tumors Expected to Dose in Q4 2022 –BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug application (IND) for MRT-2359, a potent and selective GSPT1-directed MGD. The company is on track with initia
- GlobeNewswire
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates
– Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid Tumors – – Cash Runway into Late 2024 with $299.5 Million in Cash, Cash Equivalents, Restricted Cash and Marketable Securities as of June 30, 2022 – BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business hig